This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Relmada Therapeutics’s 8K filing here.
Relmada Therapeutics Company Profile
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
Featured Stories
- Five stocks we like better than Relmada Therapeutics
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- 3 Stocks to Consider Buying in October
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- What Are Dividend Contenders? Investing in Dividend Contenders
- How Cigna Remains at the Top of the Health Insurance Food Chain
